Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Bio Green Med Solution (NASDAQ: BGMS): Understanding the Fire-Safety Company's Pending Merger

Bio Green Med Solution, Inc (NASDAQ: BGMS) is headquartered in Kuala Lumpur, Malaysia, and operates in the industrials sector. Its business centers on distributing, trading and installing protective and fire-safety materials and equipment, along with fire protection and prevention systems. Despite the "Med" in …

Nitish Kishor | 10 September 2026

Rafarma Pharmaceuticals (OTC: RAFA): A Sub-Penny Generic Drugmaker's Limited Disclosure

Rafarma Pharmaceuticals describes itself as a multi-product pharmaceutical company focused onManufacturingand selling generic antibiotics, specialty medicines and anti-cancer drugs, with operations oriented toward Russian and international markets. The company is incorporated in Wyoming and its shares trade on the OTC Markets rather than a …

Nitish Kishor | 10 September 2026

Beyond Air (NASDAQ: XAIR): LungFit's Commercial Ramp and Recent Financing

Beyond Air is a commercial-stage company built around its LungFit platform, which generates nitric oxide from ambient air. Its lead product, LungFit PH, is cleared to treat term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension. Over recent quarters the company …

Nitish Kishor | 10 September 2026

Matinas BioPharma (NYSE American: MTNB): The Deal Reshaping the Company Into Clean Energy

Matinas BioPharma built its reputation on a lipid nanocrystal (LNC) delivery platform and its lead candidate MAT2203, an oral formulation of the antifungal amphotericin B aimed at serious invasive fungal infections. On July 13, 2026, the company changed course dramatically. It signed a definitive …

Nitish Kishor | 10 September 2026

Eagle Pharmaceuticals (OTC: EGRX): From Nasdaq Drugmaker to Distressed Micro-Cap

Eagle Pharmaceuticals historically built its portfolio around injectable and specialty hospital products, including established franchises in oncology support and critical-care medicines, alongside efforts to broaden its pipeline. The company's trajectory changed sharply in 2024, when it disclosed that it had fallen behind on required …

Nitish Kishor | 10 September 2026

YourWay Cannabis Brands (OTC: YOURF): A Snapshot of a Distressed Sub-Penny Stock

YourWay Cannabis Brands describes itself as a company that, through subsidiaries, manufactures, distributes and sells cannabis in the U.S. recreational and medicinal markets. It is a Canadian-incorporated entity, tied to Vancouver, British Columbia, with a U.S. operational presence associated with Phoenix, Arizona, and its …

Nitish Kishor | 10 September 2026

Outset Medical (NASDAQ: OM): Margin Progress Against a Compressed Valuation

Outset Medical is a medical-technology company built around the Tablo Hemodialysis System, a compact console that integrates water purification, on-demand dialysate production, and connected software. The design targets both acute-care settings and, increasingly, the home, where Outset hopes to expand access to dialysis. The …

Nitish Kishor | 10 September 2026

Mosaic ImmunoEngineering (OTC: CPMV): A Small Cancer-Immunotherapy Developer's Progress

Mosaic ImmunoEngineering, based in Huntington Beach, California, is a development-stage biotechnology firm founded in 2020 that focuses on advancing immunotherapies for cancer. Its scientific heritage is rooted in plant-virus immunotherapy, and the ticker CPMV nods to cowpea mosaic virus, a plant virus studied as …

Nitish Kishor | 10 September 2026

Limitless X Holdings (OTC: LIMX): Rebuilding Sales in a Crowded Wellness Market

Limitless X Holdings is a diversified consumer packaged goods company focused on the nutrition, wellness and beauty sectors. Its model combines product development with direct-response advertising,Digital Marketingservices and direct-to-consumer e-commerce. Recent developments describe an effort to broaden the platform and stabilise the business: the …

Nitish Kishor | 10 September 2026

Aldeyra Therapeutics (NASDAQ: ALDX): Reproxalap's Path After a Third FDA Rejection

Aldeyra Therapeutics is a clinical-stage biotechnology company built around reactive aldehyde species (RASP) modulation, an anti-inflammatory approach. Its lead candidate, reproxalap, is a topical treatment aimed at the signs and symptoms of dry eye disease, a large and competitive ophthalmology market. The pivotal moment …

Nitish Kishor | 10 September 2026
Support

Hi! How can we help you today?

Loading…